iBio
IBIO
19 hedge funds and large institutions have $2.06M invested in iBio in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
19% more funds holding
Funds holding: 16 → 19 (+3)
0% less ownership
Funds ownership: 0% → 0% (-0%)
5% less capital invested
Capital invested by funds: $2.16M → $2.06M (-$104K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$51.6K |
| 2 |
Millennium Management
New York
|
+$31.5K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$28.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMG
Patton Albertson Miller Group
Chattanooga,
Tennessee
|
-$28K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$15K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.6K |
| 5 |
KTC
Kistler-Tiffany Companies
Berwyn,
Pennsylvania
|
-$1K |
IBIO Hedge Fund Activity: Q1 2016 in Review
19 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2016, worth a combined $2.06M — down 4.8% from $2.16M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IBIO positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $51.6K. The largest seller was Patton Albertson Miller Group, exiting entirely with an estimated $28K sold.
- 19 institutional investors held iBio (IBIO) as of Q1 2016, up from 16 in Q4 2015.
- Funds reported $2.06M of iBio stock for Q1 2016, down 4.8% quarter-over-quarter.
- 5 funds opened new iBio positions in Q1 2016 and 2 closed out, a net change of +3 holders.
- The largest iBio buyer in Q1 2016 was Goldman Sachs, an estimated $51.6K added.
- The largest iBio seller in Q1 2016 was Patton Albertson Miller Group, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2016.